Renato Aguilera, Ph.D., a professor of organic sciences at The College of Texas at El Paso, holds up a vial of pyronaridine, an anti-malarial drug that he not too long ago patented to be used in most cancers remedies. As a longtime most cancers researcher, Aguilera realized that the molecular construction of pyronaridine might be helpful in combating most cancers cells. Credit score: The College of Texas at El Paso
Can a drug that is used to deal with malaria be repurposed to battle most cancers? Researchers at The College of Texas at El Paso have secured a patent for the anti-malarial drug pyronaridine to just do that. Pyronaridine has been used to deal with the mosquito-borne infectious illness for over 30 years.
The invention is the results of a serendipitous encounter at UTEP.
Renato Aguilera, Ph.D., a UTEP professor of organic sciences, attended a college seminar concerning the drug in 2017. As a longtime most cancers researcher, Aguilera realized that the molecular construction of pyronaridine might be helpful in combating most cancers cells.
“Louis Pasteur said ‘Chance favors the prepared mind.’ When I looked closely at the structure of the drug, I saw that it could be used to attack cancer cells,” Aguilera stated. “Several years later, the granting of the patent is getting us closer to actually using this drug for patient care.”
Together with then doctoral scholar Paulina Villanueva, Ph.D., Aguilera performed intensive lab analysis to establish how pyronaridine interacts with most cancers cells.
In 2018, they printed a analysis paper within the journal PLOS One outlining their findings that, in take a look at tubes, the drug slows the replication of most cancers and induces “cellular suicide” in leukemia, lymphoma, melanoma, a number of myeloma, lung, ovarian and breast most cancers cells.
Most cancers cells multiply a lot quicker than regular cells within the physique, Aguilera defined, which ends up in the most cancers spreading and a worsening prognosis for the affected person.
Of their analysis, Aguilera and Villanueva discovered that pyronaridine interfered with the exercise of an enzyme referred to as topoisomerase II, which helps most cancers cells replicate, thus slowing the development of most cancers development. Together with slowing them down, it additionally spurred the most cancers cells into “programmed cell death,” a course of by which cells successfully commit suicide.
Furthermore, the drug didn’t have an effect on regular cells that weren’t quickly dividing, leaving wholesome cells intact whereas killing the most cancers cells, Aguilera stated.
“With pyronaridine, we have the trifecta: slowed growth of cells, programmed cell death, and minimal impact on healthy cells,” Aguilera stated. “In the future, this drug could potentially be used in combination with immunotherapy to speed up the process of killing cancer cells.”
Pyronaridine has been efficiently examined in some animals, Aguilera stated, and a pilot research on terminally unwell sufferers with late-stage breast, lung and liver cancers by pharmaceutical agency Armaceutica confirmed elevated longevity. However Aguilera cautioned that earlier than pyronaridine can be utilized to deal with most cancers in most of the people, it should bear scientific trials, a yearslong course of that exams medication to make sure their security and efficacy in people.
Villanueva is now a postdoctoral analysis scholar on the NanoScience Know-how Heart on the College of Central Florida. Throughout her doctoral program at UTEP, Villanueva performed a lot of the analysis that led to the invention of pyronaridine as an anti-cancer drug.
“It’s incredible to witness the hard work invested in this research come to fruition,” Villanueva stated. “Research opens the door to countless possibilities, and although personalized medicine isn’t one-size-fits-all, the drug pyronaridine could be a breakthrough for some. “The journey is not over but—there’s nonetheless a lot to be accomplished—however securing the drug’s patent is a major milestone that can drive future progress.”
The drug was patented this spring in partnership with Armaceutica, which works to develop remedies for most cancers. The patent, which is granted by the USA Patent and Trademark Workplace, acknowledges Aguilera because the inventor and mental property proprietor on the subject of the usage of pyronaridine for most cancers.
Offered by
College of Texas at El Paso
Quotation:
Frequent malaria drug repurposed to battle most cancers (2025, March 4)
retrieved 4 March 2025
from https://medicalxpress.com/information/2025-03-common-malaria-drug-repurposed-cancer.html
This doc is topic to copyright. Other than any honest dealing for the aim of personal research or analysis, no
half could also be reproduced with out the written permission. The content material is offered for data functions solely.
